$BRKR

Munch Mark sold $120K of BRKR

Munch Mark (EXEC VP&PRES BRUKER NANO INC.) sold 2,000 shares of BRUKER CORP (BRKR) at $60.25 ($0.12M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Munch Mark
Published Jul 16, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
medium confidence
Mentioned
$BRKR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and confirms the sale was executed under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article provides only one transaction and does not indicate whether there were offsetting buys, changes in total insider holdings beyond the post-sale figure, or broader company news.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-16 for a sale executed on 2026-07-15.

Background

This is an SEC Form 4 insider transaction disclosure for Bruker Corp, reported by an executive officer associated with Bruker Nano.

Company-level read

Ticker impact

$BRKRNeutralMedium confidence
Context

Bruker Corp insider Form 4 shows exec VP and Pres Bruker Nano sold 2,000 shares on 2026-07-15 at $60.25 via a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying new operational or financial information.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Insider selling can still reflect private caution, even if executed under 10b5-1, especially if multiple recent sales cluster.

Key entities

  • BRUKER CORP

    Company whose insider transaction is disclosed on Form 4.

  • Munch Mark

    Executive VP and Pres, Bruker Nano, who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that governs the timing of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.

$BRKRMed

Why Bruker (BRKR) Stock Is Falling Today

Bruker (BRKR) shares fell 6.3% after UBS initiated coverage with a Neutral rating and a $65 price target, citing AI-related tailwinds and ongoing headwinds. The company's stock has been volatile, with a 17.7% drop last month due to missed revenue expectations and lowered guidance. BRKR is up 13.1% YTD but trades 15.5% below its 52-week high.

$BRKRHighAI 8/10

Bruker (BRKR) Wagers On Fusion Energy While Wall Street Waits

Bruker (BRKR) announced a supply collaboration with Luvata to scale up production of RRP superconductors for fusion energy. BEST unit revenue grew 11.9% YoY to $74.2M in Q2, with non-GAAP EPS at $0.49. GAAP results showed a $65.3M loss due to goodwill impairments. Bruker maintains full-year non-GAAP EPS growth target of 15-17%.

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.